DeepMed Research

Nathan S. Kline Institute for Psychiatric Research

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Employees: -

Market Cap: -

Website: http://www.rfmh.org

Clinical Trials

Varenicline for Cognitive Deficits and Cigarette Smoking in Schizophrenia - Efficacy and Predictors

Phase 4

Completed

Conditions: Cigarette Smoking
Schizophrenia

Interventions: Drug: Placebo for varenicline
Drug: Varenicline

First Posted Date: 2008-12-05

Last Posted Date: 2017-12-02

Lead Sponsor: Nathan Kline Institute for Psychiatric Research

Target Recruit Count: 93

Registration Number: NCT00802919

Locations: 🇺🇸
Manhattan Psychatirc Center, New York, New York, United States
🇺🇸
Nathan Kline Insitute for Psychiatric Research, Orangeburg, New York, United States
🇨🇳
Peking University Institute of Mental Health, Beijing, China

and more 1 locations

Efficacy and Tolerability Study of Betahistine to Ameliorate Antipsychotic Associated Weight Gain

Phase 2

Completed

Conditions: Schizophrenia
Schizoaffective Disorder
Bipolar NOS(Not Otherwise Specified)
Autism Spectrum Disorder
Psychotic Disorder Not Otherwise Specified
Schizophreniform Disorder
Bipolar II
Bipolar I Disorder

Interventions: Drug: Placebo Oral Tablet
Drug: Betahistine

First Posted Date: 2008-07-03

Last Posted Date: 2019-01-25

Lead Sponsor: Nathan Kline Institute for Psychiatric Research

Target Recruit Count: 48

Registration Number: NCT00709202

Locations: 🇺🇸
Nathan Kline Insitute for Psychiatric Research, Orangeburg, New York, United States

Sodium Oxybate in Schizophrenia With Insomnia

Phase 2

Completed

Conditions: Schizophrenia
Insomnia Related to Schizophrenia (307.42)

Interventions: Drug: Sodium Oxybate

First Posted Date: 2008-01-15

Last Posted Date: 2016-02-08

Lead Sponsor: Nathan Kline Institute for Psychiatric Research

Target Recruit Count: 8

Registration Number: NCT00594256

Locations: 🇺🇸
Nathan Kline Insitute for Psychiatric Research, Orangeburg, New York, United States

Varenicline Effects In Schizophrenic Smokers

Phase 4

Completed

Conditions: Schizophrenia
Tobacco Use Disorder
Nicotine Dependance

Interventions: Drug: Varenicline

First Posted Date: 2007-10-24

Last Posted Date: 2018-09-20

Lead Sponsor: Nathan Kline Institute for Psychiatric Research

Target Recruit Count: 14

Registration Number: NCT00548470

Locations: 🇺🇸
Manhattan Psychiatric Center, New York, New York, United States

Adjunctive Glycine for Obsessive Compulsive Disorder

Not Applicable

Completed

Conditions: Obsessive Compulsive Disorder

Interventions: Other: placebo
Drug: glycine

First Posted Date: 2006-11-30

Last Posted Date: 2016-12-16

Lead Sponsor: Nathan Kline Institute for Psychiatric Research

Target Recruit Count: 24

Registration Number: NCT00405535

Locations: 🇺🇸
The Nathan Kline Institute for Psychiatric Research, Orangeburg, New York, United States

Effect of High-Dose B-Complex Vitamins on the Symptoms of Schizophrenia

Not Applicable

Completed

Conditions: Schizophrenia
Schizoaffective Disorder

Interventions: Dietary Supplement: Capsule with folate, Vitamin B12 & pyridoxine
Other: placebo

First Posted Date: 2006-11-23

Last Posted Date: 2007-08-23

Lead Sponsor: Nathan Kline Institute for Psychiatric Research

Target Recruit Count: 50

Registration Number: NCT00403247

Locations: 🇺🇸
The Nathan Kline Institute for Psychiatric Research, Orangeburg, New York, United States

Safety and Effectiveness of D-serine in Schizophrenia

Phase 2

Completed

Conditions: Schizophrenia

Interventions: Drug: D-serine

First Posted Date: 2006-05-04

Last Posted Date: 2020-10-05

Lead Sponsor: Nathan Kline Institute for Psychiatric Research

Target Recruit Count: 55

Registration Number: NCT00322023

Locations: 🇺🇸
The Nathan S. Kline Institute for Psychiatric Research, Orangeburg, New York, United States
🇺🇸
Yale University School of Medicine, New Haven, Connecticut, United States
🇺🇸
The Zucker Hillside Hospital, Glen Oaks, New York, United States

Risperidone Alone Vs. Risperidone Plus Valproate in the Treatment of Patients With Schizophrenia and Hostility

Phase 4

Completed

Conditions: Schizophrenia

First Posted Date: 2006-03-29

Last Posted Date: 2006-03-29

Lead Sponsor: Nathan Kline Institute for Psychiatric Research

Target Recruit Count: 46

Registration Number: NCT00308360

Locations: 🇺🇸
Nathan S Kline Institute for Psychiatric Research and Rockland Psychiatric Center, Clinical Research and Evaluation Facility, Orangeburg, New York, United States

Comparative Effects of Chronic Treatment With Olanzapine and Risperidone on Glucose and Lipid Metabolism

Phase 4

Completed

Conditions: Schizophrenia
Diabetes
Metabolic Syndrome
Hyperglycemia

Interventions: Drug: olanzapine
Drug: risperidone

First Posted Date: 2006-02-07

Last Posted Date: 2011-07-25

Lead Sponsor: Nathan Kline Institute for Psychiatric Research

Target Recruit Count: 46

Registration Number: NCT00287820

Locations: 🇺🇸
Manhattan Psychaitric Center, New York, New York, United States

Pioglitazone as a Treatment for Lipid and Glucose Abnormalities In Patients With Schizophrenia

Phase 4

Completed

Conditions: Diabetes
Schizophrenia
Insulin Resistance
Cognitive Impairment

Interventions: Drug: Pioglitazone
Behavioral: Life style diet group
Other: Placebo

First Posted Date: 2005-10-04

Last Posted Date: 2017-12-11

Lead Sponsor: Nathan Kline Institute for Psychiatric Research

Target Recruit Count: 56

Registration Number: NCT00231894

Locations: 🇺🇸
Nathan Kline Institute for Psychiatric Research, New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy